Tb-DOTA-chCE7 was evaluated in groups of ten mice by monitoring the tumour size of subcutaneous IGROV1 tumours. Results The average number of DOTA ligands per antibody was 2.5 and maximum specific activities of 600 MBq/mg were achieved under identical radiolabelling conditions. RICs were stable in human plasma for at least 48 h. Tb-DOTA-chCE7 showed high tumour uptake (37.8-39.0 %IA/g, 144 h p.i.) with low levels in off-target organs. SPECT/CT images confirmed the biodistribution data.
Abstract
Purpose The L1 cell adhesion molecule (L1CAM) is considered a valuable target for therapeutic intervention in different types of cancer. Recent studies have shown that anti-L1CAM radioimmunotherapy (RIT) with 67 Cu-and 177 Lu-labelled internalising monoclonal antibody (mAb) chCE7 was effective in the treatment of human ovarian cancer xenografts. In this study, we directly compared the therapeutic efficacy of anti-L1CAM RIT against human ovarian cancer under equitoxic conditions with the radiolanthanide 177 Lu and the potential alternative 161 Tb in an ovarian cancer therapy model. Methods Tb was produced by neutron bombardment of enriched 160 Gd targets. 161 Tb and 177 Lu were used for radiolabelling of DOTA-conjugated antibodies. The in vivo behaviour of the radioimmunoconjugates (RICs) was assessed in IGROV1 tumour-bearing nude mice using biodistribution experiments and SPECT/CT imaging. After ascertaining the maximal tolerated doses (MTD) the therapeutic impact of 50 % MTD of 177 Lu-and 161
Tb-DOTA-chCE7 was evaluated in groups of ten mice by monitoring the tumour size of subcutaneous IGROV1 tumours. Results The average number of DOTA ligands per antibody was 2.5 and maximum specific activities of 600 MBq/mg were achieved under identical radiolabelling conditions. RICs were stable in human plasma for at least 48 h. 177 Lu-and 161 Tb-DOTA-chCE7 showed high tumour uptake (37.8-39 .0 %IA/g, 144 h p.i.) with low levels in off-target organs. SPECT/CT images confirmed the biodistribution data. 161 Tb-labelled chCE7 revealed a higher radiotoxicity in nude mice (MTD: 10 MBq) than the 177 Lu-labelled counterpart (MTD: 12 MBq). In a comparative therapy study with equitoxic doses, tumour growth inhibition was better by 82.6 % for the 161 Tb-DOTAchCE7 than the 177 Lu-DOTA-chCE7 RIT. Conclusions Our study is the first to show that anti-L1CAM 161 Tb RIT is more effective compared to 177 Lu RIT in ovarian cancer xenografts. These results suggest that
Introduction
Ovarian cancer is a gynaecological malignancy with high mortality, because it is often diagnosed late. Approximately 75 % of the patients will have already developed metastases at Electronic supplementary material The online version of this article (doi:10.1007/s00259-014-2798-3) contains supplementary material, which is available to authorized users. the time of diagnoses, and debulking surgery is still the crucial step in ovarian cancer therapy [1] . Some success has been achieved in the treatment of ovarian cancer during the last few decades, but the largest percentage of patients will have a relapse with a median progression-free survival of 18 months [2] . New therapeutic approaches with antibodies and/or selective kinase inhibitors (targeted therapy) have not made any significant improvement for patients until now [3, 4] . Overall mortality due to ovarian cancer remains unchanged, and new therapeutic strategies to control the disease are very desirable.
The L1 cell adhesion molecule (L1CAM) is a highly glycosylated type I transmembrane protein that is overexpressed in various tumours and is considered a promising target for novel therapies (reviewed in: [5] [6] [7] [8] [9] ). The aberrant expression of L1CAM is associated with tumour cell invasion and motility [7] , and with poor prognosis and a high risk for progression in ovarian, uterine, and colorectal cancers [10] [11] [12] . The restricted expression of L1CAM in normal tissue [13] has led to the use of anti-L1CAM monoclonal antibodies in targeted ovarian cancer therapies [14] [15] [16] [17] . To increase the efficacy of antibody-based L1CAM therapy, we introduced 67 Cu [16] and 177 Lu [15] for radioimmunotherapy (RIT) in ovarian cancer therapy models. The choice of the therapeutic low-ß¯-energy emitting nuclides for RIT matches the size of small residual disease found after tumour resection in ovarian cancer patients. The used monoclonal antibody chCE7 is a chimeric IgG1 molecule that binds with high affinity to human L1CAM. We could demonstrate that chCE7 binds near the RGD sequence in the sixth Ig-like domain of human L1CAM and can prevent the binding to integrins [18] . The antigen-antibody complex internalised by endocytosis [19] and metallic radionuclides like 67 Cu or 177 Lu were trapped intracellularly. Limiting factors for a more widespread use of 67 Cu in preclinical and clinical evaluations is probably due to the limited availability of 67 Cu and due to the production-related limited specific activity that can be reached.
In this study, we directly compared the electron (ß¯) emitters Tb for RIT. Both radionuclides are similar with respect to half-life (6.7 and 6.9 days, respectively), ß¯-energy (mean 134 keV vs. 154 keV), and chemical properties, and emit low-energy photons suited for gamma camera imaging. The main difference between these two lanthanides is the number of emitted conversion and Auger electrons (referred to as Auger electrons).
161
Tb emits 16 times more Auger electrons per decay (3-50 keV) than 177 Lu (Table 1) . Auger electrons produce short-range damage that may have an advantage for the eradication of small tumour nodules. In this study, we compared biodistributions and therapeutic anticancer efficacies of 177 Lu-and 161 Tb-DOTAchCE7 immunoconjugates in human ovarian tumour-bearing nude mice under equitoxic conditions.
Materials and methods

Cell lines and antibodies
IGROV1 human ovarian carcinoma cells were obtained from Istituto Nazionale per lo Studio e la Cura dei Tumori (Milano, Italy). Cells were analysed by STR profiling (DSMZ, Braunschweig, Germany). Cell culture conditions and antibodies are described in Supplementary Information (SI).
L1CAM expression on IGROV1 cells L1CAM expression on IGROV1 cells was analysed by flow cytometry (SI).
Conjugation of antibodies to DOTA and radiolabelling
Conjugation of antibodies to DOTA was performed as previously described [15] . The molar excess of p-SCN-Bn-DOTA (Macrocyclics, Dallas, TX, USA) was adapted individually for the different antibodies to achieve a similar number of DOTA-ligands coupled to the antibodies. The reaction mixture was adjusted to pH 9-10 using a saturated Na 3 PO 4 solution and was incubated overnight (16 h) at 4°C. Excess ligands were removed by gel filtration chromatography on a NAP-5 column (GE Healthcare, Glattbrugg, Switzerland) which was eluted with 0.25 M ammonium acetate (pH 5.5) for labelling. The number of chelators coupled per mAb molecule was determined by mass spectrometry [15] .
Immunoconjugates were stored at −80°C until use.
Carrier-free 161 Tb was produced in-house by irradiation of highly enriched gadolinium-160 targets at the spallationinduced neutron source at Paul Scherrer Institute (PSI, Villigen, Switzerland) or at the high-flux nuclear reactor at the Institut Laue-Langevin (Grenoble, France) and separated by cation exchange chromatography as described before [20] . 177 Lu was obtained from ITG (Garching, Munich, Germany). Both radionuclides were used for radiolabelling according to published procedures [21] . Briefly, 200-1,000 μg of the immunoconjugates in a total volume of 500 or 900 μL of 0.25 M ammonium acetate buffer (pH 5.5) was reacted with 100-600 MBq of 177 Lu or 161 Tb solution at 37°C for 1 h. After incubation, EDTA was added to a final concentration of 5 mmol/L and the mixture was incubated for 5 min to complex unchelated lutetium or terbium. Purification of the labelled antibodies was achieved by fast protein liquid chromatography (FPLC) size exclusion chromatography on a Superose 12 column (GE Healthcare, Glattbrugg, Switzerland) in phosphate buffered saline (PBS) with a flow rate of 0.5 mL/min. Fractions of 500 μL were collected and the major peak fractions were pooled.
Quality control of radiolabelled preparations
The immunoreactive fraction of labelled antibody conjugates was measured by cell-binding assays and data were analysed according to the Lindmo method [22] . Stability of the labelled antibodies after incubation in human plasma at 37°C was analysed by FPLC size exclusion chromatography on a TSKgel G3000Wxl column (Tosoh Bioscience, Stuttgart, Germany) with sodium phosphate buffer (0.3 M NaCl, 0.05 M Na 2 HPO 4 , pH 6.2) as mobile phase at a flow rate of 1 mL/min.
Biodistribution and SPECT/CT imaging
Animal studies were conducted in compliance with the Swiss laws on animal protection. All experiments were approved by the cantonal committee on animal experiments and permitted by the responsible cantonal authorities (permission numbers 75528 and 75535). Housing and animal husbandry was conducted according to local law on animal protection. Female CD1-foxn1 nu mice, 4-5 weeks old (Charles River, Sulzfeld, Germany) were inoculated subcutaneously (right shoulder) with 7×10 6 IGROV1 cells and biodistribution studies and SPECT/CT (NanoSPECT/CT, Bioscan Europe; Paris, France) imaging were performed 14 days later. Tb-DOTAchCE7 (6, 8, 10 , and 12 MBq; each 65 μg mAb). After injection, mice were weighed every other day and monitored daily for humane endpoint. After 2 weeks, we changed the inspection intervals to every third day until the end of the experiment (47 days). The maximum tolerated dose (MTD) is defined as the first dose level below the dose leading to >20 % decrease in total body weight in at least one of the mice, or an early reaching of a defined endpoint of at least one mouse [23] . Peripheral blood mononuclear cell (PBMC) viability was analysed 13 days post i.v. injection of RICs in whole peripheral blood using the Guava ViaCount assay (Guava Technologies, Cardiff, UK) measured on a guava easyCyte flow cytometer (Millipore, Zug, Switzerland) according to the instructions given by the supplier.
Radioimmunotherapy experiments
Based on the results of the dose escalation studies, RIT studies were performed in female nude mice (eight per group) with subcutaneous tumours (IGROV1 human ovarian carcinoma, mean volume 133±50 mm Tb, maximum specific activities of 600 MBq/mg antibody have been achieved under identical reaction conditions.
Aggregates, small fragments, and free radionuclides were separated from the radiolabelled antibody fraction by FPLC size exclusion chromatography. The immunoreactivity of the antibodies analysed by cell binding assays ranged from 78 to 84 %. Both radioimmunoconjugates were stable in human plasma at 37°C for at least 48 h. No sign of degradation, release of radioactivity or aggregation was observed (SI).
Comparative biodistribution of Tb-DOTA-chCE7 allowed an excellent visualization of implanted L1CAM-expressing ovarian carcinomas (Fig. 1) Tb-labelled RICs. The images showed low blood activities and low activities in liver and other organs which leads to the low background. The labelled unspecific isotope-matched antibodies did not accumulate at the tumour side (Fig. 1b, d) . Tb-labelled mAb chCE7 can be based on experimentally determined maximum tolerated dose (MTD). The dose escalation study was done in groups of four non-tumour bearing nude mice treated with 8, 10, 12, or 14 MBq 177 Lu-DOTAchCE7 (Fig. 2a) Tb-DOTA-chCE7 (Fig. 2b) . The amount of the injected RICs was adjusted to 65 μg. Within the first 10 days, one mouse died unexpectedly in the 12 MBq 177 Lu-DOTA-chCE7 group. This death was not regarded as related to the application of the RIC (no signs of distress, no change in behaviour, and no radiation syndrome), and therefore, it was not taken into the evaluation.
Twelve to 14 days after administration of the highest dose of radioactivity ( Tb-labelled immunoconjugate) we observed a significant decrease in body weight for almost all mice in these treatment groups (Fig. 2a, b) . The mice looked pale; their agility dropped, and mice showed signs of distress and acute radiation syndrome. A representative picture of such a mouse is shown in (SI). At the same time, the number of red blood cells Tb-DOTA-chCE7 (5 MBq) induced prominent tumour growth retardation compared with mice that received corresponding control treatments (Fig. 3) . The effect of 50 % MTD of 177 Lu-DOTA-chCE7 (6 MBq) was less prominent. After a short delay phase, the mean relative tumour volume (RTV) in all control groups increased roughly linearly and increased three times compared to therapy started after a tumour growth delay (TGD) of 40 days (in the case of 161 Tb-DOTA-unspecific matched control IgG), 47 days (in the case of 177 Lu-DOTA-unspecific matched control IgG) and 54 days (in the case of PBS). In both anti-L1CAM targeted therapy groups, a mean three-fold increase of the start RTV was not reached, because the first mouse in these groups attained the endpoint before. Therefore, we calculated the TGD in these groups with a RTV increase of 2.3 for 
Discussion
In this study, we investigated the efficacy of anti-L1CAM radioimmunotherapy using mAb chCE7 labelled with 177 Lu or 161 Tb. For both radiolanthanides, we used the same labelling procedures and obtained stable radiolabelled DOTA conjugated antibodies with high specific activities. Biodistribution studies showed that both radioconjugates distributed similarly in tumour-bearing nude mice. The immunoreactivity of both radioconjugates was equal. Terbium and lutetium have similar ionic radii (Tb: 0.923 Å; Lu: 0. 861 Å) for six-coordinate complexes [24, 25] , and both lanthanides build extremely stable complexes with DOTA ligands [26] , which is reflected in the low uptake of radioactivity in bones. It has been described that nude mice exhibit often-different endogenous IgG concentrations that can influence blood pool, spleen and liver uptake of injected mAbs [27, 28] . To Lu-DOTA-chCE7 in one mouse at 144 h post injection. The mouse showed unusually low activity in tumour and organs (SI). We assume that this low activity was due to a small amount of administered antibody. This mouse was not considered for statistical analysis. The clear SPECT/CT images confirmed the biodistributions we obtained for both radioconjugates. Therefore, both radiolanthanides are suitable Tb-labelled chCE7 antibodies, we determined the MTD for both radioimmunoconjugates. Tumour-free mice were chosen for the dose escalation study to simulate the worst case, i.e. no tumour accumulation of the antibody. Consequently, the RICs follow their biological half-life in blood and distribute without accumulation at a tumour site in the body. For the dose escalation study we used 65 μg of labelled antibody per mouse (resulting from the highest dose that was given) to exclude the influence of endogenous IgG concentrations and to hold the conditions for the whole dose range constant. The higher radiotoxicity of mAb 161 Tb-DOTAchCE7 (MTD: 10 MBq) compared to 177
Lu-DOTA-chCE7 (MTD: 12 MBq) is certainly caused in part by the higher ßē nergy emitted by 161 Tb. This is in agreement with observations of Brouwers et al. [29] who found a low MTD of 5.6 MBq for a 90 Y-labelled internalising chimeric antibody in nude mice. Yttrium-90 has mean ß¯energy of 900 keV. It is most likely that the additional Auger and conversion electrons emitted by 161 Tb influenced the radiotoxicity too. The shortrange electrons exert their greatest toxicity effects only after internalisation or on the cell membrane of the target cell [30] [31] [32] [33] . Inside the cell, Auger electrons are able to deposit high energy around the decay site which leads to ionisation and excitations, chemical transmutations, local effects of charged species, and nuclear recoil [30, 34] . The biological effects induced by Auger electrons are, for the most part, indirectly caused [30] . The significance of intracellular position near the cell nucleus has been discussed [30, [34] [35] [36] . In this context, the group of Reilly reported that nuclear localizing sequences coupled to an 111 In-labelled antibody promoted specific nuclear uptake in tumour cells and enhanced the radiotoxicity of the antibody [37, 38] . On the other hand, Guo et al. [39] showed that an increased nuclear uptake of the Auger emitter 64 Cu in a radioimmunotherapy regime of HCT116 tumour-bearing nude mice had no advantage. In this comparative RIT study between 177 Lu-and 161 Tb-labelled monoclonal antibodies using 50 % MTD we could clearly demonstrate that the 161 Tb-labelled mAb chCE7 performed much better than the 177 Lu-labelled counterpart. The differences were significant and tumour growth inhibition was 82.6 % higher for 161 Tb-DOTA-chCE7 vs. 177 Lu-DOTAchCE7. We assume that the better therapeutic efficacy of 161 Tb-RIT is the result of both the higher ß¯energy and the 16-fold higher emission rate of conversion and Auger electrons. More than half of these electrons (3-50 keV) emitted by 161 Tb have an energy higher than 16 keV. This could explain why a nuclear localization is not necessary for the great effect of 161 Tb. It is known that Auger electrons induce bystander effects, which can harm neighbouring cells [40] . This may Lu-DOTA chCE7 treatment) or b) a 2.5-fold increase of the RTV (for the also have influenced the therapeutic efficacy of the RIT. At present, dosimetric estimations are not able to reflect all radiobiological responses induced by conversion and Auger electrons [35] .
Conclusions
Our study is, to our knowledge, the first to show that Tb is potentially the better candidate for RIT with internalisation antibodies. Next, we will investigate if we can optimise the RIT with 161 Tb in combination with radiosensitising agents, and we will analyse the exact molecular mechanisms of the radiobiological effects induced by the Auger electrons.
